Ajanta Pharma
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Ajanta Pharma's management has articulated a strategic shift towards specialty pharmaceuticals, emphasizing growth in branded generics, particularly in the US and emerging markets. This transition is expected to drive revenue growth, with management projecting high-teen growth for FY27, supported by a robust pipeline of complex generics and ongoing capacity expansion. Vista's financial outlook aligns with this, forecasting stable revenue growth and improving margins, bolstered by disciplined R&D spending and a focus on high-margin products. However, potential headwinds such as rising input costs and geopolitical instability in key markets could pose risks to profitability. The Indian pharmaceutical sector's expansion, driven by favorable currency dynamics and resilient demand for chronic therapies, provides a supportive backdrop for Ajanta's growth. Over the next 12-24 months, key opportunities include successful product launches and market share gains, while watchpoints include regulatory challenges and operational cost pressures that could impact margins
Why We Like This Stock
- Management's strategic shift towards specialty pharmaceuticals is expected to enhance revenue growth and margins
- Strong performance in branded generics, particularly in the US and Africa, supports a positive revenue outlook
- Ongoing capacity expansion and a robust pipeline of complex generics position the company for long-term growth
Things To Watch Out For
- Rising input costs and geopolitical instability may pressure profit margins and operational efficiency
- Potential regulatory hurdles in the US market could impact the timely launch of new products
- Increased competition in the biosimilars space may affect profitability and market share
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 4,209 | 4,648 | 5,453 | 5,977 | 6,829 |
| Profit Before Tax (Cr.) | 1,103 | 1,183 | 1,378 | 1,538 | 1,763 |
| PBT Margin | 26.2% | 25.5% | 25.3% | 25.7% | 25.8% |
| Net Profit (Cr.) | 808 | 872 | 1,078 | 1,208 | 1,385 |
| Earnings Per Share | 64.3 | 69.5 | 85.9 | 96.3 | 110.4 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| ICICI Securities | ► Hold | 3,260 | 31-Jul-2026 |
| Jeffries | ▲ Buy | 4,050 | 31-Jul-2026 |
| Motilal Oswal | ▲ Buy | 4,000 | 31-Jul-2026 |
| Prabhudas Liladhar | ▲ Buy | 3,730 | 31-Jul-2026 |
| BOB Capital Markets | ▲ Buy | 3,347 | 06-May-2026 |
| Elara Capital | ► Accumulate | 3,115 | 05-May-2026 |
Company Overview
Show Company Profile
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.